Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International Inc    BAX

Delayed Quote. Delayed  - 10/24 10:00:41 pm
48.44 USD   +0.54%
10/24 BAXTER INTERNAT : Launches HDx Therapy Enabled by THERANOVA to Provi..
10/24 BAXTER INTERNAT : Research Reports on Healthcare Equities -- Valeant..
10/21 GLOBAL BLOOD TE : Abbott Laboratories, Ortho Clinical Diagnostics, B..
News SummaryMost relevantAll newsSector news 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
12/10/2012 | 03:34pm CEST
    By Saabira Chaudhuri 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
10/24 BAXTER INTERNATIONAL : Launches HDx Therapy Enabled by THERANOVA to Provide High..
10/24 BAXTER INTERNATIONAL : Research Reports on Healthcare Equities -- Valeant Pharma..
10/21 GLOBAL BLOOD TESTING MARKET 2016 : Abbott Laboratories, Ortho Clinical Diagnosti..
10/21 BAXTER INTERNATIONAL : EuroLife Health Acquires Baxter Indias FFS Infusion Busin..
10/21 BAXTER INTERNATIONAL : Eurolife buys baxter india's ffs infusions business
10/20 BAXTER INTERNATIONAL INC : Change in Directors or Principal Officers (form 8-K)
10/20 BAXTER INTERNATIONAL : New Data Show Malnutrition in U.S. Hospitals Associated w..
10/20 BAXTER INTERNATIONAL : Patent Issued for Packaging System (USPTO 9463138)
10/20 BAXTER INTERNATIONAL : Vaughan David Investments INC Lowered Its Baxter Internat..
10/20BAXTER INTERNATIONAL INC : quaterly earnings release
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
10/19DJST JUDE MEDICAL : Sales Rise 12% -- Update
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/18DJST JUDE MEDICAL : Forms Cybersecurity Advisory Group
10/14 Private equity firms line up bids for BSN Medical - sources
10/11DJST JUDE MEDICAL : Warns of Battery Problems With Heart Products -- 3rd Update
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
10/24 Notable earnings before Tuesday?s open
09/29 CSL Behring's long-acting hemophilia B treatment Idelvion approved in Japan
09/20 Shire cools to pacritinib, intends to return to CTI Biopharma
09/19 Baxter launches NUMETA G13E in Europe for preterm newborns at risk for malnut..
09/16 Healthcare ratings roundup - new coverage
Financials ($)
Sales 2016 10 153 M
EBIT 2016 1 224 M
Net income 2016 2 971 M
Debt 2016 198 M
Yield 2016 1,02%
P/E ratio 2016 7,29
P/E ratio 2017 27,96
EV / Sales 2016 2,60x
EV / Sales 2017 2,51x
Capitalization 26 205 M
More Financials
Duration : Period :
Baxter International Inc Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Full-screen chart
Technical analysis trends BAXTER INTERNATIO...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 16
Average target price 51,0 $
Spread / Average Target 5,9%
Consensus details
EPS Revisions
More Estimates Revisions
José E. Almeida Chairman, President & Chief Executive Officer
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
John D. Forsyth Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC9.09%115 958
C R BARD INC15.80%16 114
TERUMO CORP9.70%14 919
More Results